Cas:1284248-73-2 cis-3-Aminocyclopentanol hydrochloride manufacturer & supplier

We serve Chemical Name:cis-3-Aminocyclopentanol hydrochloride CAS:1284248-73-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

cis-3-Aminocyclopentanol hydrochloride

Chemical Name:cis-3-Aminocyclopentanol hydrochloride
CAS.NO:1284248-73-2
Synonyms:3-Aminocyclopentanol hydrochloride (1:1);Cyclopentanol, 3-amino-, hydrochloride (1:1)
Molecular Formula:C5H12ClNO
Molecular Weight:137.608
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:46.25000
Exact Mass:137.060745
LogP:1.36080

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-Aminocyclopentanol hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclopentanol, 3-amino-, hydrochloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cyclopentanol, 3-amino-, hydrochloride (1:1) Use and application,Cyclopentanol, 3-amino-, hydrochloride (1:1) technical grade,usp/ep/jp grade.


Related News: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. 9-[(2S,3S)-(2,3-isopropylidenedioxy-5-trityloxy-4-pentanone)-1-yl]-6-methoxypurine manufacturers When these modified cells are given back to the patient, they are transported in the bloodstream to the bone marrow where they start to make healthy red blood cells that produce beta-globin. The effects of Zynteglo are expected to last for the patient’s lifetime. (Z)-2-(2-oxoindolin-3-ylidene)-N-(3-(piperidin-1-yl)propyl)hydrazine-1-carbothioamide suppliers After speaking to iRhythm on Tuesday, J.P. Morgan analysts wrote we shouldn’t expect an update on reimbursement before the release of the Physician Fee Schedule proposed rule in July/August. 3-Bromoniatricyclo[3.2.1.02,4]octa-2(4),6-diene vendor & factory.